Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04231591 · ClinicalTrials.gov registry record
NT-proBNP Levels in the Prediction of Intrapartum and Postpartum Events in Adult Congenital Heart Disease Patients
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 34
- Enrollment target
NCT04231591: Completed study, sponsored by Mayo Clinic.
NCT04231591 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04231591 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if NT-BNP levels obtained at time of admission for delivery are predictive of intrapartum or postpartum complications in patients with adult congenital heart disease.
Primary Outcome
Incidence of heart failure, incidence of arrhythmia, incidence of cardiac arrest
Interventions
- DIAGNOSTIC_TEST NT-proBNP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2023-12-01 |
What the finished NCT04231591 record still lists
NCT04231591 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which NT-proBNP is the first listed.
NCT04231591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04231591 about?
NCT04231591 is a clinical study titled "NT-proBNP Levels in the Prediction of Intrapartum and Postpartum Events in Adult Congenital Heart Disease Patients". The purpose of this study is to determine if NT-BNP levels obtained at time of admission for delivery are predictive of intrapartum or postpartum complications in patients with adult congenital heart disease.
What is the current status of trial NCT04231591?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2019-11-13. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT04231591?
The interventions under investigation include: NT-proBNP (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04231591?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI